103 related articles for article (PubMed ID: 24183933)
1. An analysis of temozolomide-related adverse drug reactions reported to the medicines and healthcare products regulatory agency through the yellow card scheme aiming to characterise idiosyncratic profound bone marrow suppression tantamount to aplastic anaemia.
Dixit S; Hingorani M; Allgar V
Clin Oncol (R Coll Radiol); 2014 Feb; 26(2):120-1. PubMed ID: 24183933
[No Abstract] [Full Text] [Related]
2. Temozolomide induced bone marrow Suppression--A single institution outcome analysis and review of the literature.
Kourelis TV; Buckner JC; Gangat N; Patnaik MM
Am J Hematol; 2015 Sep; 90(9):E183-4. PubMed ID: 26010271
[No Abstract] [Full Text] [Related]
3. Bone marrow transplantation for severe aplastic anemia secondary to temozolomide.
Morris EB; Kasow K; Reiss U; Ellison D; Broniscer A
J Neurooncol; 2009 Jan; 91(2):237-9. PubMed ID: 18818880
[TBL] [Abstract][Full Text] [Related]
4. A rare case of aplastic anemia caused by temozolomide.
George BJ; Eichinger JB; Richard TJ
South Med J; 2009 Sep; 102(9):974-6. PubMed ID: 19668033
[TBL] [Abstract][Full Text] [Related]
5. Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide.
Villano JL; Collins CA; Manasanch EE; Ramaprasad C; van Besien K
Lancet Oncol; 2006 May; 7(5):436-8. PubMed ID: 16648049
[No Abstract] [Full Text] [Related]
6. Higher dosing of temozolomide? Regression of an anaplastic oligoastrocytoma over more than three years.
Koch D; Wick W
J Neurooncol; 2006 Apr; 77(2):219-20. PubMed ID: 16292485
[No Abstract] [Full Text] [Related]
7. Hematologic adverse events associated with temozolomide.
Villano JL; Letarte N; Yu JM; Abdur S; Bressler LR
Cancer Chemother Pharmacol; 2012 Jan; 69(1):107-13. PubMed ID: 21614470
[TBL] [Abstract][Full Text] [Related]
8. [Phototoxicity of dacarbazine (Deticene) not reinduced by temozolomide (Temodal)].
Schmutz JL; Barbaud A; Trechot P
Ann Dermatol Venereol; 2006 May; 133(5 Pt 1):500. PubMed ID: 16760848
[No Abstract] [Full Text] [Related]
9. Temozolomide for melanoma: new toxicities and new opportunities.
Gajewski TF
J Clin Oncol; 2004 Feb; 22(4):580-1. PubMed ID: 14726506
[No Abstract] [Full Text] [Related]
10. Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?
Khasraw M; Bell D; Wheeler H
J Clin Neurosci; 2009 Jun; 16(6):854-5. PubMed ID: 19303779
[TBL] [Abstract][Full Text] [Related]
11. How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience.
Wick W; Weller M
J Clin Oncol; 2005 Jun; 23(18):4235-6; author reply 4236. PubMed ID: 15961774
[No Abstract] [Full Text] [Related]
12. Rapid desensitization with temozolomide in patients with delayed maculopapular rash.
Alonso-Llamazares A; Vega-Castro A; Beitia-Mazuecos JM; Mateo-Borrega B; Cardenas-Contreras R
J Investig Allergol Clin Immunol; 2012; 22(6):448-9. PubMed ID: 23101195
[No Abstract] [Full Text] [Related]
13. Successful rapid desensitization to temozolomide: A case series.
Divekar R; Butterfield J; Maddox D
J Allergy Clin Immunol Pract; 2016; 4(3):545-6. PubMed ID: 26868726
[No Abstract] [Full Text] [Related]
14. Is protracted low-dose temozolomide feasible in glioma patients?
Wong ET
Neurology; 2006 Aug; 67(3):543-4; author reply 543-4. PubMed ID: 16894133
[No Abstract] [Full Text] [Related]
15. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
16. Non-Hodgkin's lymphoma in a patient on treatment with temozolomide.
Otty Z; Sabesan S
Asia Pac J Clin Oncol; 2012 Dec; 8(4):e53-4. PubMed ID: 22897453
[TBL] [Abstract][Full Text] [Related]
17. Is protracted low-dose temozolomide feasible in glioma patients?
Tosoni A; Cavallo G; Ermani M; Scopece L; Franceschi E; Ghimenton C; Gardiman M; Pasetto L; Blatt V; Brandes AA
Neurology; 2006 Feb; 66(3):427-9. PubMed ID: 16476947
[TBL] [Abstract][Full Text] [Related]
18. An Australian experience with temozolomide for the treatment of recurrent high grade gliomas.
Harris MT; Rosenthal MA; Ashley DL; Cher L
J Clin Neurosci; 2001 Jul; 8(4):325-7. PubMed ID: 11437571
[TBL] [Abstract][Full Text] [Related]
19. Unusual and severe symptomatic impairment of neutrophil function after one cycle of temozolomide in patients with malignant glioma.
Hartmann P; Herholz K; Salzberger B; Petereit HF
Ann Hematol; 2004 Apr; 83(4):212-7. PubMed ID: 14648028
[TBL] [Abstract][Full Text] [Related]
20. Clinical and histological features of idiosyncratic acute liver injury caused by temozolomide.
Grant LM; Kleiner DE; Conjeevaram HS; Vuppalanchi R; Lee WM
Dig Dis Sci; 2013 May; 58(5):1415-21. PubMed ID: 23212393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
